Forums
3 posts
• Page 1 of 1
Dr. McCarthy's Projects
We have read from a remarkable project that will be started soon by your institute Roswell Park in myeloma research. Could you describe us that promising project? Perhaps it's interesting for readers, who want to participate in that trials. There's a lot of chatter about it in the myeloma forums.
Re: Dr. McCarthy's Projects
Hi,
This is a reply to Mr. Parker. I assume this is not Peter Parker of Spiderman fame? We opened a Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) study BMT-CTN 0702 that examines a single autotransplant versus a tandem transplant versus a single transplant followed by Revlimid/Velcade/Dexamethasone (RVD) consolidation for 4 cycles. All patients receive 3 years of lenalidomide maintenance. This study has been opened in multiple centers around the USA and will examine the question of single transplant versus two versus a single with consolidation following transplant. So, we are offering this study to patients who are transplant eligible. Any induction therapy is allowed on this study. Drs. Amrita Krishnan and George Somlo from City of Hope and Dr. Ed Stadtmauer from UPenn are the PIs of this study. Dr. Asher Chanan Khan from RPCI has an open study examining the use of an anti CD 56 antibody alone or with lenalidomide and dexamethasone for relapsed multiple myeloma. His group presented early promising results at ASH 2010 meeting. Further there is another study examining upfront transplant versus later transplant for newly diagnosed multiple myeloma patients. This is a French and American study that is being led by Dr. Paul Richardson in the USA and Dr. Michel Attal from the French Myeloma Intergroup (IFM). This study examines induction therapy followed by stem cell collection and then a randomization to transplant versus more chemotherapy. The chemotherapy arm could get transplant at relapse. Lastly as part of our participation in the BMT CTN 0702 study, we have proposed a correlative laboratory science study with Drs. Marcelo Pasquini from the BMT-CTN, Dr Theresa Hahn and Dr Paul Wallace from RPCI to examine the use of flow cytometry to detect minimal residual disease following therapy and correlate this with outcome. So, these are some of the highlights of research at the local and cooperative group level.
This is a reply to Mr. Parker. I assume this is not Peter Parker of Spiderman fame? We opened a Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) study BMT-CTN 0702 that examines a single autotransplant versus a tandem transplant versus a single transplant followed by Revlimid/Velcade/Dexamethasone (RVD) consolidation for 4 cycles. All patients receive 3 years of lenalidomide maintenance. This study has been opened in multiple centers around the USA and will examine the question of single transplant versus two versus a single with consolidation following transplant. So, we are offering this study to patients who are transplant eligible. Any induction therapy is allowed on this study. Drs. Amrita Krishnan and George Somlo from City of Hope and Dr. Ed Stadtmauer from UPenn are the PIs of this study. Dr. Asher Chanan Khan from RPCI has an open study examining the use of an anti CD 56 antibody alone or with lenalidomide and dexamethasone for relapsed multiple myeloma. His group presented early promising results at ASH 2010 meeting. Further there is another study examining upfront transplant versus later transplant for newly diagnosed multiple myeloma patients. This is a French and American study that is being led by Dr. Paul Richardson in the USA and Dr. Michel Attal from the French Myeloma Intergroup (IFM). This study examines induction therapy followed by stem cell collection and then a randomization to transplant versus more chemotherapy. The chemotherapy arm could get transplant at relapse. Lastly as part of our participation in the BMT CTN 0702 study, we have proposed a correlative laboratory science study with Drs. Marcelo Pasquini from the BMT-CTN, Dr Theresa Hahn and Dr Paul Wallace from RPCI to examine the use of flow cytometry to detect minimal residual disease following therapy and correlate this with outcome. So, these are some of the highlights of research at the local and cooperative group level.
-
Dr. Philip McCarthy - Name: Philip McCarthy Jr., M.D.
To Dr. McCarthy
Dr. McCarthy,
how could you assume, that I'm not the Spider- Peter Parker. Of course I am. The first Superhero with multiple myeloma. Dr. McCarthy - thank you for your kind answers!!!
Peter
how could you assume, that I'm not the Spider- Peter Parker. Of course I am. The first Superhero with multiple myeloma. Dr. McCarthy - thank you for your kind answers!!!
Peter
-
Peter Parcer
3 posts
• Page 1 of 1
Return to Treatments & Side Effects